Tag Archives: Eckert & Ziegler SE

Eckert & Ziegler Supports Development of DARPin Radiolabeled Cancer Therapies Using Actinium-225 and Lutetium-177

(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, … Read the full press release

Empowering Radiopharmaceutical Innovation: A Global Supply Pact Between Eckert & Ziegler and AtomVie

(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release